Sanofi investors hungry for drug progress and deal news

PARIS (Reuters) - Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.